Nutriband Inc. (FRA:9WV)

Market Cap	51.24M
Revenue (ttm)	2.25M
Net Income (ttm)	-28.05M
Shares Out	n/a
EPS (ttm)	-2.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	3.880
Previous Close	4.480
Day's Range	3.880 - 3.880
52-Week Range	3.620 - 9.850
Beta	n/a
RSI	37.72
Earnings Date	Dec 3, 2025

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company has commercial development and clinical supply agre...

• Industry: Pharmaceutical Preparations
• Founded: 2016
• Country: United States
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9WV

Financial Performance

In 2024, Nutriband's revenue was $2.14 million, an increase of 2.60% compared to the previous year's $2.09 million. Losses were -$10.48 million, 91.1% more than in 2023.

Financial numbers in USD